medwireNews: EULAR has announced the launch of a European pediatric and adult registry to monitor the outcomes of patients with rheumatic and musculoskeletal diseases who develop COVID-19.
“This is a European effort working closely with the COVID-19 Global Rheumatology Alliance,” said EULAR in a press release, noting that anonymized data collected by the European registry will be shared with the global database.
EULAR asks that rheumatologists from countries that are part of EULAR or the Paediatric Rheumatology European Society report all cases, regardless of severity, to the EULAR-COVID-19 database only, to avoid duplication of records. If cases have been reported to a national database, they should not be reported again in the EULAR registry.
“There is an urgent need to understand outcomes of patients who acquire COVID-19 and are receiving steroids, synthetic or biologic disease-modifying anti-rheumatic drugs, and non-steroidal anti-inflammatory drugs,” said Pedro Machado, Chair of the EULAR Standing Committee of Epidemiology and Health Services Research.
“This will help guide rheumatologists and other clinicians such as specialist nurses in advising and caring for their patients,” he added.
medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature Group
1 April 2020: The coronavirus pandemic is affecting all healthcare professionals across the globe. Medicine Matters’ focus, in this difficult time, is the dissemination of the latest data to support you in your research and clinical practice, based on the scientific literature. We will update the information we provide on the site, as the data are published. However, please refer to your own professional and governmental guidelines for the latest guidance in your own country.